Lowe Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Lowe syndrome, also known as the oculocerebrorenal syndrome of Lowe (OCRL), is a complex multisystem disorder characterized by abnormalities affecting the eye, nervous system, and kidney. At birth, affected individuals display bilateral cataracts and severe hypotonia. Within the following weeks or months, they develop a proximal renal tubulopathy (Fanconi-type) and may experience complications in the eye, such as glaucoma and the formation of cheloids. During childhood, psychomotor retardation becomes apparent, while behavioral issues become more prominent, and renal complications emerge during adolescence. This condition results from a mutation in the OCRL1 gene, found on the Xq26.1 chromosome, which encodes the enzyme phosphatidylinositol (4,5) bisphosphate 5 phosphatase, also known as PtdIns (4,5)P2, located in the trans-Golgi network. Both enzymatic and molecular tests are available for confirming the diagnosis and detecting prenatal disease. It’s important to note that similar ocular symptoms, like bilateral cataracts and hypotonia, can also be present at birth in cases of congenital infections (e.g., rubella), peroxisomal disorders, mitochondriopathies, or myotonic congenital dystrophies and congenital myopathies (e.g., Muscle-Eye-Brain disease, MEB). However, the appearance of renal involvement differentiates Lowe syndrome from these alternative diagnoses within the first few months of life. Treatment for Lowe syndrome involves several approaches, including cataract removal, managing glaucoma, providing physical and speech therapy, administering medications to address behavioral problems, and correcting tubular acidosis and bone disease using bicarbonate, phosphate, potassium, and water. Unfortunately, the life expectancy for individuals with Lowe syndrome rarely exceeds 40 years.

Thelansis’s “Lowe Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lowe Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Lowe Syndrome across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Lowe Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Lowe Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033